Diabetic Nephropathy Serum
Diabetic Nephropathy Serum from IRB-consented donors with confirmed diabetic kidney disease, a microvascular complication of diabetes. Suitable for creatinine and cystatin C assay development, renal function and fibrosis biomarker discovery, and renoprotective therapy research. eGFR and albuminuria stratification available.
Diabetic Nephropathy Serum for Diabetic Kidney Disease Research
Our Diabetic Nephropathy Serum is sourced from IRB-consented donors clinically diagnosed with diabetic nephropathy. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality. Diabetic nephropathy is a microvascular complication of diabetes in which sustained hyperglycaemia, haemodynamic stress and metabolic injury damage the glomerular filtration barrier, producing progressive albuminuria and loss of filtration function. This serum supports nephrology biomarker discovery, renal function assay development and therapeutic research.
Glomerular Injury, Renal Function Biology and Why Serum
- Chronic hyperglycaemia drives advanced glycation end-product formation, oxidative stress and haemodynamic changes that injure podocytes, mesangial cells and the glomerular endothelium — a metabolic microvascular process, not autoimmunity.
- Structural hallmarks include glomerular basement membrane thickening, mesangial expansion and podocyte loss, which together degrade the filtration barrier and permit albumin leakage.
- Loss of filtration capacity raises circulating creatinine and cystatin C, the analytes underlying estimated glomerular filtration rate; both are measured in serum, making serum the standard matrix for renal function work.
- Progressive disease is accompanied by secondary changes measurable in serum, including altered mineral and bone metabolism markers, anaemia-related indices and rising inflammatory and fibrosis-associated mediators.
- Established renin–angiotensin system blockade and newer SGLT2 inhibitor and mineralocorticoid receptor antagonist therapies make treatment-stratified serum valuable for pharmacodynamic and biomarker work.
- Serum is acellular. It suits clinical chemistry, immunoassay, proteomic and metabolomic analysis; no cell-based or immunophenotyping assays are performed on this matrix.
Donor Stratification Available
- CKD stage by eGFR category where documented
- Albuminuria category by urine albumin-to-creatinine ratio where documented
- Underlying diabetes type: type 1 versus type 2 diabetes
- Glycaemic control as reflected in documented HbA1c
- Treatment status: ACE inhibitor or ARB, SGLT2 inhibitor, mineralocorticoid receptor antagonist, GLP-1 receptor agonist, or untreated
- Diabetes duration and presence of other microvascular complications such as retinopathy or neuropathy
- Matched healthy controls available, including diabetic donors without nephropathy
Product Features
- Collected from clinically confirmed diabetic nephropathy donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported medical history and comorbidities
- Renal function and glycaemic laboratory values where available
- Concurrent medications, including renoprotective therapy where reported
Applications
- Creatinine and cystatin C assay development and eGFR method comparison
- Biomarker discovery for progression of diabetic kidney disease
- Serum cytokine, chemokine and fibrosis-associated mediator profiling
- Advanced glycation end-product and oxidative stress marker research
- Serum proteomic and metabolomic discovery studies
- Mineral and bone metabolism marker characterisation in progressive CKD
- Pharmacodynamic and treatment response research for renoprotective therapies
- Clinical chemistry assay validation across impaired renal function ranges
Other Diabetic Nephropathy Specimen Types
- Diabetic Nephropathy Plasma
- Diabetic Nephropathy Whole Blood
- Diabetic Nephropathy PBMC
- Diabetic Nephropathy Leukopak
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Diabetic nephropathy serum is available in standard and custom volumes. For pricing, current availability, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse donor cohorts across our full inventory, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.